What Is Pasithea Therapeutics Corp. (KTTA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Pasithea Therapeutics Corp. is potentially undervalued at its current price of $0.48. Based on our 13-model framework, Pasithea Therapeutics Corp.'s intrinsic value is estimated at a composite fair value of $1.34 — representing +181.3% implied upside — with 6 out of 7 active models confirming this thesis. Model dispersion is worth noting: First Chicago targets $2.18 (+357.0%), versus PWERM at $0.49 (+3.1%). This +353.9% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About KTTA?
7 of 13 models are currently active for KTTA. All 7 active models suggest the stock trades below fair value. The Bayesian DCF estimates KTTA's intrinsic value at $0.96, implying +100.7% upside from the current price. See which stocks rank higher →
How Does KTTA Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, KTTA ranks #223 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to biopharma enterprise businesses. For Pasithea Therapeutics Corp., metrics like patent cliff exposure provide important context that general-purpose valuation models may underweight.
Is KTTA a Value Trap?
CirclFi's Value Trap algorithm assigns KTTA a score of 25/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Pasithea Therapeutics Corp.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Pasithea Therapeutics Corp. scores 4.9 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +353.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every KTTA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across KTTA's 7 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad